Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.
Blood · 2026-Mar-12 · PMID 41385341
OS
Figure 2. Survival probabilities and the cumulative incidence of primary and secondary end point events. (A) The cGFS (the primary end point) after Orca-T or Tac/MTX prophylaxis over 1 year. The shaded areas indicate 95% simultaneous confidence bands. (B) The cumulative incidence of moderate-to-severe cGVHD over 1 year. (C) The OS probability over 1 year. (D) The survival free from grade 3 to 4 acute GVHD, moderate-to-severe cGVHD, or relapse (GRFS) over 1 year. For the estimates of the secondary end point events, 95% CIs for survival and cumulative incidence at 1 year (panels B-D) are provided, but they have not been adjusted for multiplicity and should not be used for hypothesis testing.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T19:16:29+00:00 |